Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease. - Wikidata - awgldk - TriplyDB

Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease.

Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease.

http://www.wikidata.org/entity/Q35864072

about

Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib Determination of the most appropriate method for extrapolating overall survival data from a placebo-controlled clinical trial of lenvatinib for progressive, radioiodine-refractory differentiated thyroid cancer.Autophagy: A potential target for thyroid cancer therapy (Review)Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models Multikinase inhibitors use in differentiated thyroid carcinoma.Molecular profiling of thyroid cancer subtypes using large-scale text mining.Potential anti-cancer effect of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a novel histone deacetylase inhibitor, for the treatment of thyroid cancer.Serum microRNA profiling to distinguish papillary thyroid cancer from benign thyroid masses.Patient Benefit-Risk Tradeoffs for Radioactive Iodine-Refractory Differentiated Thyroid Cancer Treatments MicroRNA expression profiles in differentiated thyroid cancer, a review Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer Controversies in the management and followup of differentiated thyroid cancer: beyond the guidelines.A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer Thyroglobulin fluctuations in patients with iodine-refractory differentiated thyroid carcinoma on lenvatinib treatment - initial experience.Phosphatidylinositide 3-kinase (PI3K) and PI3K-related kinase (PIKK) activity contributes to radioresistance in thyroid carcinomas.Lenvatinib: A Review in Refractory Thyroid Cancer.Impact of early vs late postoperative radioiodine remnant ablation on final outcome in patients with low-risk well-differentiated thyroid cancer.18F-FDG Pet-Guided External Beam Radiotherapy in Iodine-Refractory Differentiated Thyroid Cancer: A Pilot Study.Papillary thyroid carcinoma expressing CD20.Whole-remnant and maximum-voxel SPECT/CT dosimetry in 131 I-NaI treatments of differentiated thyroid cancer.Tyrosine kinase inhibitors for advanced or metastatic thyroid cancer: a meta-analysis of randomized controlled trials.Prolonged duration of response in lenvatinib responders with thyroid cancer.

P2860

Q26863326-D1ACD6D0-8D7F-4504-AD71-B7DCF5D1268F Q27853034-60310D47-0E0B-4158-B860-A706D9B2B5D7 Q31114848-41BCDEBA-7EF4-429A-AC3E-E3148A994701 Q33933013-3E1CF6A5-0538-4901-916F-4298873D5E82 Q34253418-B0E56864-B738-4C65-9AAA-E4346F869E37 Q34660901-56B925B9-4193-4AA8-965E-5B14B7498684 Q34914970-965C83C7-3D70-46A6-AFF4-036516CB03CD Q35876617-A5778DFA-C646-4F22-9B2B-9BFF2567B750 Q36030561-28AE0C6B-8B14-42B3-A6B9-D460700B8E66 Q36366960-98C37F1C-1D54-413B-83B6-75B093A8A680 Q36449793-5CA4E3A2-B6EB-4CFD-B1C9-4E64483B03C9 Q36467394-2B4DC181-FC08-4BBD-9B6E-7A072DDDD00A Q36530119-7D126EAC-1B3B-4938-8B47-669089A86C84 Q36716739-5986EDB4-0952-45B1-A0E0-FAA983C90E61 Q36924717-3F097FFA-CB9B-4193-8142-99FA99DDDD06 Q37010592-8F6B6C60-B877-4AA4-B891-CA1526A4C60C Q37665265-2C5E3E24-69BC-4670-AC74-42279E9B4D38 Q38729953-D11A951D-DA76-4787-A151-CD046DBCDA61 Q44819667-2F3D0AAB-3F7C-4A99-BAD9-02B506A3C2FF Q47114573-0B4615C6-3E4D-4337-808F-1E6B65D679AE Q50583371-2ED1E159-3CC6-4090-8BEE-72C36F90E709 Q50943856-254E8976-3CC7-4BDD-9921-63CD4211FA27 Q53109364-AC88A731-EE74-493A-8A72-F4AEC3657735 Q55413273-1A1E2B1C-D5C3-4872-ABB2-4299C75A6A94

P2860

Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease.

http://www.wikidata.org/entity/Q35864072

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Differentiated thyroid cancer: ...... oiodine nonresponsive disease.

@ast

Differentiated thyroid cancer: ...... oiodine nonresponsive disease.

@en

type

label

Differentiated thyroid cancer: ...... oiodine nonresponsive disease.

@ast

Differentiated thyroid cancer: ...... oiodine nonresponsive disease.

@en

prefLabel

Differentiated thyroid cancer: ...... oiodine nonresponsive disease.

@ast

Differentiated thyroid cancer: ...... oiodine nonresponsive disease.

@en

P1433

Q35864072-02F1B626-9347-4FD2-B4EB-89CAACC96A44

P1476

Q35864072-06E8BDD4-E0EB-42D9-8DD4-32149AD57146

P2093

Q35864072-595FEEDC-92AE-4AE2-9461-1E793F6A4532

Q35864072-D047801F-2FF5-4314-9E07-6C6E4A11566B

P2860

Q35864072-0416DF38-4191-4C38-94C1-D11EE6576883

Q35864072-071CA7C0-0C8B-4307-B37A-82B41824242B

Q35864072-09C9429A-E417-425F-B50D-B56BEE640A74

Q35864072-1715EDAC-B828-4A65-9DAE-E8AFAB733B65

Q35864072-1B6DD4B8-9410-4CA2-BCEB-FFFFD7562C77

Q35864072-24DD5C3B-2EED-45C2-9C45-8E7F11C2480B

Q35864072-2C8F1DD3-7B84-4CAF-A04E-2BD8668B85CF

Q35864072-2D4F00E5-716D-444F-AD34-CC44B8D4E99D

Q35864072-357180AC-719C-4C9B-A874-4D83868CFE09

Q35864072-395C1A13-5438-42BC-9D44-15D219270D29

P304

Q35864072-05DCD81F-3634-44B6-AC9C-1983C98DCF9C

P31

Q35864072-C7B54FFE-A3E3-4755-8B21-F3DE7DBC7F85

P356

Q35864072-3F74894A-8BD9-40CA-AEA9-5E12F4A9D82E

P478

Q35864072-1E2DF0C2-FD3E-404A-829A-197E90B28D74

P577

Q35864072-B40F53A2-4A3E-4AD0-95C5-9BC9AE9D0CFA

P5875

Q35864072-4B50DBC4-82D8-437D-BD45-DCE44ED09698

P698

Q35864072-27DFA3D9-3D45-46B4-8BA0-8B1255EF8A4B

P932

Q35864072-10FC5B6A-7B05-4651-9C84-282389DE2615

P356

P1433

Journal of Thyroid Research

P1476

Differentiated thyroid cancer: ...... oiodine nonresponsive disease.

@en

P2093

Maria E Cabanillas

http://www.w3.org/2001/XMLSchema#string

Naifa Lamki Busaidy

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer

Cancer statistics, 2009

Mechanisms of angiogenesis and arteriogenesis

Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer.

Locally advanced thyroid cancer: therapeutic options.

Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma.

Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan.

Evaluation and treatment of aerodigestive tract invasion by well-differentiated thyroid carcinoma.

P304

618985

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2012/618985

http://www.w3.org/2001/XMLSchema#string

P478

2012

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224822302

http://www.w3.org/2001/XMLSchema#string

P698

22530159

http://www.w3.org/2001/XMLSchema#string

P932

3316972

http://www.w3.org/2001/XMLSchema#string